Cargando…

Patient‐reported outcomes following autologous stem cell transplant for patients with multiple myeloma

We evaluated changes in patient‐reported outcomes and cognitive function from pre‐ to 3–6 months post‐treatment among 42 newly diagnosed patients with multiple myeloma undergoing transplant with complete data using PROMIS‐29. There were statistically significant improvements in physical (p < .001...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biran, Noa, Zhai, Wanting, Jensen, Roxanne E., Mandelblatt, Jeanne, Kumka, Susan, Unawane, Rashmi, Graves, Kristi D., Vesole, David H, Siegel, David S, Potosky, Arnold L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176031/ https://www.ncbi.nlm.nih.gov/pubmed/35844688 http://dx.doi.org/10.1002/jha2.231

Ejemplares similares

I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients
por: Gill, Sarvarinder K., et al.
Publicado: (2022)

Adaptation and Evaluation of a Symptom-Monitoring Digital Health Intervention for Patients With Relapsed and Refractory Multiple Myeloma: Pilot Mixed-Methods Implementation Study
por: Biran, Noa, et al.
Publicado: (2020)

Examination of individual and multiple comorbid conditions and health-related quality of life in older cancer survivors
por: Siembida, Elizabeth J., et al.
Publicado: (2021)

Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up
por: Biran, N, et al.
Publicado: (2016)

Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial
por: Biran, Noa, et al.
Publicado: (2021)

Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma
por: Martin, Thomas G., et al.
Publicado: (2021)

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
por: Biran, Noa, et al.
Publicado: (2019)

Carfilzomib induced cardiotoxicity in a multiple myeloma patient
por: Méndez-Toro, Arnold, et al.
Publicado: (2020)

Interaction between age and gender on survival outcomes in extramedullary multiple myeloma over the past two decades
por: Bangolo, Ayrton I, et al.
Publicado: (2023)

EPIGENETIC AGING IN OLDER BREAST CANCER SURVIVORS: THE THINKING AND LIVING WITH CANCER (TLC) STUDY
por: Rentscher, Kelly, et al.
Publicado: (2022)

A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
por: Alsina, Melissa, et al.
Publicado: (2020)

IS THE INTERNATIONAL STAGING SYSTEM SUPERIOR TO THE DURIE SALMON STAGING SYSTEM? A COMPARISON IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANT
por: Hari, Parameswaran N., et al.
Publicado: (2009)

Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma
por: Charliński, Grzegorz, et al.
Publicado: (2021)

Chemotherapy promotes astrocytic response to Aβ deposition, but not Aβ levels, in a mouse model of amyloid and APOE
por: Ng, Christi Anne S., et al.
Publicado: (2022)

High levels of circulating CD34+ cells at autologous stem cell collection are associated with favourable prognosis in multiple myeloma
por: Raschle, J, et al.
Publicado: (2011)

SECOND TRANSPLANTS FOR MULTIPLE MYELOMA RELAPSING AFTER A PRIOR AUTOTRANSPLANT – REDUCED INTENSITY ALLOGENEIC VERSUS AUTOLOGOUS TRANSPLANTATION
por: Freytes, Cesar O., et al.
Publicado: (2013)

Radiation therapy at the end of life: a population-based study examining palliative treatment intensity
por: Kress, Marie-Adele Sorel, et al.
Publicado: (2015)

Enhancement of clonogenicity of human multiple myeloma by dendritic cells
por: Kukreja, Anjli, et al.
Publicado: (2006)

The Results of Autologous Skin Test in Patients with Chronic Urticaria in Hamadan, Iran
por: Safari, Mojgan, et al.
Publicado: (2016)

Interrupted Identities: Autologous Stem Cell Transplant in Patients With Multiple Myeloma
por: Halpin, Sean N, et al.
Publicado: (2021)

Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation
por: Jantunen, Esa, et al.
Publicado: (2023)

Primary therapy with single agent bortezomib as induction, maintenance, and re-Induction in patients with high risk myeloma: results of the ECOG E2A02 trial
por: Dispenzieri, Angela, et al.
Publicado: (2010)

New Rising Infection: Human Herpesvirus 6 Is Frequent in Myeloma Patients Undergoing Autologous Stem Cell Transplantation after Induction Therapy with Bortezomib
por: Horowitz, Netanel, et al.
Publicado: (2012)

Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial
por: Pawlyn, Charlotte, et al.
Publicado: (2020)

P1681: RACIAL DIFFERENCES IN DETERMINANTS OF TREATMENT DECISION-MAKING AMONG PATIENTS WITH MULTIPLE MYELOMA
por: Dwyer, Lisa, et al.
Publicado: (2023)

Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients
por: FU, CHENGCHENG, et al.
Publicado: (2013)

Autologous Graft versus Host Disease: An Emerging Complication in Patients with Multiple Myeloma
por: Batra, Anu, et al.
Publicado: (2014)

Comparison of single and double autologous stem cell transplantation in multiple myeloma patients
por: Malkan, Umit Yavuz, et al.
Publicado: (2021)

Experience of Autologous Stem Cell Transplant in Multiple Myeloma: The Patient and Caregiver Perspective
por: Hansen, Doris K, et al.
Publicado: (2023)

Effect of a 6-Week Cycle of Nordic Walking Training on Vitamin 25(OH)D(3,) Calcium-Phosphate Metabolism and Muscle Damage in Multiple Myeloma Patients–Randomized Controlled Trial
por: Czerwińska-Ledwig, Olga, et al.
Publicado: (2022)

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes
por: Hari, P, et al.
Publicado: (2017)

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation
por: Uy, Geoffrey L., et al.
Publicado: (2015)

P1690: SHARED DECISION-MAKING IN MULTIPLE MYELOMA: DO PATIENTS, CAREGIVERS, AND PHYSICIANS SHARE THE SAME GOALS AND PREFERENCES?
por: Dwyer, Lisa, et al.
Publicado: (2023)

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
por: Tremblay, Gabriel, et al.
Publicado: (2021)

Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma: Past, Present, and Future
por: Ozaki, Shuji, et al.
Publicado: (2014)

Real-word data on autologous stem cell transplantation in older patients with multiple myeloma
por: Schain, Frida, et al.
Publicado: (2019)

Prevalence and Significance of Sarcopenia in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
por: Williams, Alexis, et al.
Publicado: (2020)

Tandem Autologous Hematopoietic Stem Cell Transplantation in Very Young Patients with Multiple Myeloma
por: Naithani, Rahul, et al.
Publicado: (2020)

Impact of interval progression before autologous stem cell transplant in patients with multiple myeloma
por: Bao, Alicia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m76ss4nj24qss92hc2amj4a58q